SpotLight/SpotLight Duo with Low Dose Lung Cancer Screening Option

The Arineta SpotLight/SpotLight Duo system is designed to provide advanced cross-sectional medical imaging, notably integrating a new Low Dose Lung Cancer Screening option for enhanced early detection. This capability is achieved through new scan protocols, validated by non-clinical and clinical assessments to ensure diagnostic-quality images and substantial equivalence to existing market devices.

A regulatory review has determined that Arineta Ltd.'s SpotLight/SpotLight Duo system, including its new Low Dose Lung Cancer Screening Option, is substantially equivalent to other devices on the market for its specified uses. This clearance allows the system to be marketed for generating cross-sectional images of the body, encompassing cardiovascular and thoracic anatomies, with its newly enhanced screening capabilities. The integration of the Low Dose Lung Cancer Screening option into the SpotLight/SpotLight Duo system involves new scan protocols specifically designed for lung cancer screening in medium and large patients, aligning with professional medical society guidelines, without requiring functional or design alterations to the core system. Rigorous non-clinical bench testing confirmed the device maintains image quality metrics comparable to established counterparts, while a clinical assessment by radiologists validated its ability to produce diagnostic-quality images, even for detecting small nodules, without raising new safety or effectiveness concerns. Consequently, the device remains subject to ongoing requirements for manufacturing quality, labeling, and adverse event reporting.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What are the specific technical specifications of the new scan protocols for the Low Dose Lung Cancer Screening option, particularly regarding radiation dose reduction?; How does the SpotLight/SpotLight Duo system compare in terms of cost-effectiveness and workflow integration with existing lung cancer screening devices?; What was the methodology and patient cohort size for the clinical assessment that validated diagnostic-quality images and small nodule detection?; Are there any long-term follow-up studies planned or available to assess the clinical outcomes and true-positive/false-positive rates of screening with this device?; What specific professional medical society guidelines were adhered to for the new scan protocols, and how does the device ensure compliance?